We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Cutting Edge: Challenges in Medical and Surgical Therapies |

Acitretin- and Tumor Necrosis Factor Inhibitor –Resistant Acrodermatitis Continua of Hallopeau Responsive to the Interleukin 1 Receptor Antagonist Anakinra

Virginie Lutz, MD; Dan Lipsker, MD
Arch Dermatol. 2012;148(3):297-299. doi:10.1001/archdermatol.2011.2473.
Text Size: A A A
Published online


Acrodermatitis continua of Hallopeau is a variant of pustular psoriasis, which can be very difficult to treat. We describe a patient who could not be controlled with most approved drugs for psoriasis including acitretin, methotrexate, tumor necrosis factor (TNF) inhibitors, and ustekinumab. The interleukin 1 (IL-1) receptor antagonist anakinra was rapidly effective and allowed controlling fever and pustulation. Targeting IL-1 could be an important alternative to the classic treatments of pustular psoriasis.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Erythematosquamous eruption covered by many pustules on the hands.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. An almost complete regression of the pustules at 24 hours after the start of anakinra therapy.




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 6

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles